Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand.
Medicina (Kaunas). 2020 Nov 16;56(11):616. doi: 10.3390/medicina56110616.
Cancer-associated carbohydrate antigen 50 (CA50) is a marker for detection of gastrointestinal cancers, especially of pancreatic and colon cancer. In this study, the power of CA50 as a diagnostic and prognostic marker was evaluated in intrahepatic cholangiocarcinoma (iCCA). Serum CA50 levels of iCCA patients and non-cholangiocarcinoma controls (non-CCA, including healthy persons and patients with benign biliary diseases and other gastrointestinal cancers) were measured using MAGLUMI800 CLIA analyzer. Diagnostic and prognostic values of serum CA50 levels were evaluated. CA50 levels in the sera of iCCA patients were significantly higher than those of non-CCA controls ( < 0.001, Mann-Whitney U test). Using cut-off value of 25 U/mL, CA50 provided 65.9% sensitivity, 87.3% specificity, and 80.1% accuracy for diagnosis of iCCA. Serum CA50 levels were increased and associated with the severity of bile duct pathology. In addition, a higher level of CA50 was associated with poor clinical outcome and shorter survival in iCCA patients. Multivariate survival analysis by Cox regression model revealed the potential of CA50 as an independent poor prognostic indicator for iCCA, regardless of the age, sex, histological types, or tumor stages. CA50 can be a diagnostic and poor prognostic marker candidate for iCCA.
癌抗原 50（CA50）是一种用于检测胃肠道癌症的标志物，尤其是胰腺癌和结肠癌。本研究旨在评估 CA50 作为肝内胆管癌（iCCA）的诊断和预后标志物的作用。采用 MAGLUMI800 CLIA 分析仪检测 iCCA 患者和非胆管癌对照组（非 CCA，包括健康人群、良性胆道疾病患者和其他胃肠道癌症患者）血清 CA50 水平。评估血清 CA50 水平的诊断和预后价值。iCCA 患者血清 CA50 水平明显高于非 CCA 对照组（<0.001，Mann-Whitney U 检验）。使用 25 U/mL 的截断值，CA50 对 iCCA 的诊断具有 65.9%的敏感性、87.3%的特异性和 80.1%的准确性。血清 CA50 水平升高并与胆管病理严重程度相关。此外，CA50 水平较高与 iCCA 患者的不良临床结局和较短的生存时间相关。Cox 回归模型的多变量生存分析显示，CA50 是 iCCA 的独立不良预后指标，与年龄、性别、组织学类型或肿瘤分期无关。CA50 可作为 iCCA 的诊断和不良预后标志物候选物。
